Snapshot from May 30, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / People / David A. Sallman
Person

David A. Sallman

Tracked across 1 events · 6 articles · First seen May 12, 2026 · Last active May 12, 2026

Sentiment
10
Attention
4
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
4 10
Tech
Geron RYTELO LR-MDS Study Results
Geron Corporation announced that the first real-world evidence study of its drug RYTELO (imetelstat) in patients with lower-risk myelodysplastic syndromes (LR-MDS) will be presented at the European Hematology Association (EHA) 2026 Congress. The investigator-sponsored study,…
Impact: David A. Sallman, M.D., from H. Lee Moffitt Cancer Center & Research Institute, is a key investigator in the study and will present the data at EHA 2026.
May 12, 2026 · 6 articles
Key Actions (1)
40 David A. Sallman will present dataGeron RYTELO LR-MDS Study Results
NEWSDESK
Track David A. Sallman live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.